Health Care
Commentary
Direct-To-Consumer Sales Can Fulfill Trump’s Drug Pricing Promises
The Trump administration wants to enable more Americans to purchase prescription medications directly from manufacturers at transparent, discounted prices—thus collectively saving patients tens of billions of dollars by cutting out middlemen in the drug supply chain. Voters overwhelmingly like the president’s idea. In a recent poll, 90% of Republican voters ...
Blog
Learn How Drug Price Controls Hurt Patients
Big Pharma Is Not Gouging Americans nor Driving Up Healthcare Costs
Whether it is Sanders vilifying pharmaceutical companies or Trump’s emphasis on imposing price controls, they both allege that drug spending is a primary driver of the nation’s rising healthcare costs. Even a cursory look at the data demonstrates their focus is misplaced. Let’s start with the national health expenditure data ...
Commentary
Shut down the enhanced Obamacare subsidies, not the government
Is it worth shutting down the government to keep billions in federal cash flowing to health insurers? That’s a question Republicans should be asking Democrats every chance they get. The minority party has brought business in Washington to a halt as part of a wrongheaded strategy to obscure the out-of-control ...
Commentary
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
Drug Prices
NEW BRIEF: New California Medi-Cal Restrictions Will Hurt Patients; Competition Key to Affordable, High-Quality Health Care
SACRAMENTO – As California prepares to restrict access to proven private health insurers for dual eligible Medicare and Medi-Cal patients, the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – today released a new brief showing that expanding competition—not ...
Commentary
GOP Lawmakers Can Stand Up For Affordable Healthcare By Ending Trump’s Tariffs
Employers expect to see their health insurance costs surge by as much as 9.5% next year. That’s the biggest uptick since 2011. President Trump’s tariffs deserve much of the blame. According to analysts, the threat of new levies on imported drugs and drug ingredients is one of the main factors ...
Commentary
Seniors Will Soon Pay the Price for Biden’s Medicare Misstep
Seniors can expect to pay more for their Medicare prescription drug insurance next year. And they have the Biden administration’s signature policy achievement — the Inflation Reduction Act — to thank. According to a recent announcement by the Trump administration, Medicare Part D drug benefit premiums are expected to increase ...
Commentary
Drug Innovation is Dying in UK, Don’t Let it Happen Here
Drug companies are fleeing the United Kingdom. This month, Merck announced that it would cancel a proposed $1.3 billion research center in London and terminate all of its research and development efforts in the country. To justify its decision, the drugmaker cited “the overall undervaluation of innovative medicines and vaccines ...
Commentary
What socialized medicine really looks like
Most younger voters are rooting for a socialist president in the 2028 election, according to a new poll. In addition, more than three-quarters of voters younger than 40 believe that major industries such as health care, energy and Big Tech should be nationalized “to give more control and equity to ...
Commentary
The Administration Risks Drug Shortages That Will Cost Patients Dearly
Judged by its actions, the Trump Administration supports drug shortages. Clearly, this is not the President’s stated goal, but it is the inevitable result of his policies including his proposed drug tariffs and most favored nation (MFN) policies. Read the op-ed here.
Direct-To-Consumer Sales Can Fulfill Trump’s Drug Pricing Promises
The Trump administration wants to enable more Americans to purchase prescription medications directly from manufacturers at transparent, discounted prices—thus collectively saving patients tens of billions of dollars by cutting out middlemen in the drug supply chain. Voters overwhelmingly like the president’s idea. In a recent poll, 90% of Republican voters ...
Learn How Drug Price Controls Hurt Patients
Big Pharma Is Not Gouging Americans nor Driving Up Healthcare Costs
Whether it is Sanders vilifying pharmaceutical companies or Trump’s emphasis on imposing price controls, they both allege that drug spending is a primary driver of the nation’s rising healthcare costs. Even a cursory look at the data demonstrates their focus is misplaced. Let’s start with the national health expenditure data ...
Shut down the enhanced Obamacare subsidies, not the government
Is it worth shutting down the government to keep billions in federal cash flowing to health insurers? That’s a question Republicans should be asking Democrats every chance they get. The minority party has brought business in Washington to a halt as part of a wrongheaded strategy to obscure the out-of-control ...
When Drug Firms Stand Up to Price Controls, U.S. Patients Win
Drug maker Bristol Myers Squibb just announced plans to sell its new schizophrenia drug Cobenfy at the same price in both the United Kingdom and the United States. And if the British government refuses, the manufacturer may walk away from the market. The drug maker’s posture portends good news for ...
NEW BRIEF: New California Medi-Cal Restrictions Will Hurt Patients; Competition Key to Affordable, High-Quality Health Care
SACRAMENTO – As California prepares to restrict access to proven private health insurers for dual eligible Medicare and Medi-Cal patients, the Center for Medical Economics and Innovation at the Pacific Research Institute – the nonpartisan, California-based, free market think tank – today released a new brief showing that expanding competition—not ...
GOP Lawmakers Can Stand Up For Affordable Healthcare By Ending Trump’s Tariffs
Employers expect to see their health insurance costs surge by as much as 9.5% next year. That’s the biggest uptick since 2011. President Trump’s tariffs deserve much of the blame. According to analysts, the threat of new levies on imported drugs and drug ingredients is one of the main factors ...
Seniors Will Soon Pay the Price for Biden’s Medicare Misstep
Seniors can expect to pay more for their Medicare prescription drug insurance next year. And they have the Biden administration’s signature policy achievement — the Inflation Reduction Act — to thank. According to a recent announcement by the Trump administration, Medicare Part D drug benefit premiums are expected to increase ...
Drug Innovation is Dying in UK, Don’t Let it Happen Here
Drug companies are fleeing the United Kingdom. This month, Merck announced that it would cancel a proposed $1.3 billion research center in London and terminate all of its research and development efforts in the country. To justify its decision, the drugmaker cited “the overall undervaluation of innovative medicines and vaccines ...
What socialized medicine really looks like
Most younger voters are rooting for a socialist president in the 2028 election, according to a new poll. In addition, more than three-quarters of voters younger than 40 believe that major industries such as health care, energy and Big Tech should be nationalized “to give more control and equity to ...
The Administration Risks Drug Shortages That Will Cost Patients Dearly
Judged by its actions, the Trump Administration supports drug shortages. Clearly, this is not the President’s stated goal, but it is the inevitable result of his policies including his proposed drug tariffs and most favored nation (MFN) policies. Read the op-ed here.
